Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Thymosin α-1 vs VIP (Vasoactive Intestinal Peptide)
An educational, source-based comparison of Thymosin α-1 and VIP (Vasoactive Intestinal Peptide) — how each peptide works, what it's researched for, and what to know before going deeper.
A 28-amino-acid peptide naturally produced by the thymus. Research indicates it modulates T-cell maturation, dendritic cell function, and innate immune signaling. Approved in several countries (under the name Zadaxin) as an adjunct in hepatitis B/C and certain cancer protocols.
- Chronic viral hepatitis (approved use abroad)
- Vaccine response augmentation
- Immunosenescence
- Adjunct in oncology research
- • Approved in 35+ countries but not FDA-approved in the US.
- • Generally well tolerated in published clinical data.
- • Requires physician oversight.
Neuropeptide researched for immune modulation and lung protection.
A 28-amino-acid neuropeptide with broad immunomodulatory, anti-inflammatory, and bronchodilatory effects. Acts via VPAC1 and VPAC2 receptors to regulate T-cell function, macrophage polarization, and airway smooth muscle tone.
- Acute respiratory distress syndrome (ARDS)
- Chronic inflammatory conditions
- Autoimmune modulation
- Bronchial asthma and COPD
- • Short half-life limits therapeutic utility; analogs in development.
- • Not FDA-approved in native form.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Two cited studies; independent replication needed.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Thymosin α-1 | Thymosin alpha 1: a comprehensive review of clinical experience | Annals of the New York Academy of Sciences | 2010 | Reviews approved uses and ongoing trials across viral, oncologic, and immune indications. |
| VIP (Vasoactive Intestinal Peptide) | VIP in acute respiratory distress syndrome | Critical Care Medicine | 2021 | Demonstrated lung-protective effects in preclinical ARDS models. |
| VIP (Vasoactive Intestinal Peptide) | VIP and immune tolerance | Frontiers in Immunology | 2019 | Reviewed mechanisms of T-regulatory cell induction and immune homeostasis. |
Side-effect & safety grid
- Approved in 35+ countries but not FDA-approved in the US.
- Generally well tolerated in published clinical data.
- Requires physician oversight.
- Short half-life limits therapeutic utility; analogs in development.
- Not FDA-approved in native form.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Thymosin α-1 vs VIP (Vasoactive Intestinal Peptide) — Key differences
- Class: Thymosin α-1 is classified as Immune Modulation, while VIP (Vasoactive Intestinal Peptide) is Immune · Respiratory.
- Primary research focus: Thymosin α-1 — chronic viral hepatitis (approved use abroad); VIP (Vasoactive Intestinal Peptide) — acute respiratory distress syndrome (ards).
- Tag: Immune vs Immune · Respiratory.